Becker's Healthcare September 9, 2024
Leqembi, an Alzheimer’s drug from Biogen and Eisai, faces hurdles with respect to reimbursement and diagnostic uncertainties, diagnostic test requirements and the need for regular brain scans, CNBC reported Sept. 8.
Approved by the FDA in July 2023, Lequembi is a monoclonal antibody that does not offer a cure to the disease but has shown promise in slowing cognitive decline in early stage...